Overexpression of NMDAR2B in an inflammatory model of Alzheimer's disease: Modulation by NOS inhibitors

Brain Research Bulletin

Volumn 109, Issue , 2014, Pages 109-116

  Maher, Ahmed ^a   El Sayed, Nesrine Salah Eldine ^a,b   Breitinger, Hans Georg ^a   Gad, Mohamed Zakaria ^a  

^a German University in Cairo   (Egypt)

^b Faculty of Pharmacy   (Egypt)

Author keywords

Alzheimer; Diflunisal; LPS; Nitric oxide; NMDAR; NOS inhibitors

Indexed keywords

ARGININE; DIFLUNISAL; LIPOPOLYSACCHARIDE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2B; N [3 (AMINOMETHYL)BENZYL]ACETAMIDINE; N(G) NITROARGININE METHYL ESTER; AMIDINE; AMYLOID BETA PROTEIN; BENZYLAMINE DERIVATIVE; ENZYME INHIBITOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N-(3-(AMINOMETHYL)BENZYL)ACETAMIDINE; NITRIC OXIDE SYNTHASE; NONSTEROID ANTIINFLAMMATORY AGENT; NR2B NMDA RECEPTOR;

ALZHEIMER DISEASE; AMYLOID PLAQUE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD BRAIN BARRIER; BRAIN LEVEL; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; GENE OVEREXPRESSION; IMMUNOHISTOCHEMISTRY; LOCOMOTION; MALE; MOUSE; NONHUMAN; NOVEL OBJECT RECOGNITION TEST; OPEN FIELD TEST; SPATIAL MEMORY; Y-MAZE TEST; ANIMAL; ANTAGONISTS AND INHIBITORS; BRAIN; CHEMICALLY INDUCED; COMPLICATION; DISEASE MODEL; DRUG EFFECTS; EXPLORATORY BEHAVIOR; GENE EXPRESSION REGULATION; GENETICS; INFLAMMATION; MAZE TEST; METABOLISM; PATHOPHYSIOLOGY;

ALZHEIMER DISEASE; AMIDINES; AMYLOID BETA-PEPTIDES; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARGININE; BENZYLAMINES; BRAIN; DIFLUNISAL; DISEASE MODELS, ANIMAL; ENZYME INHIBITORS; EXPLORATORY BEHAVIOR; GENE EXPRESSION REGULATION; INFLAMMATION; LIPOPOLYSACCHARIDES; MALE; MAZE LEARNING; MICE; NG-NITROARGININE METHYL ESTER; NITRIC OXIDE SYNTHASE; RECEPTORS, N-METHYL-D-ASPARTATE;

EID: 84910048025     PISSN: 03619230     EISSN: 18732747     Source Type: Journal    
DOI: 10.1016/j.brainresbull.2014.10.007     Document Type: Article

References (46)

1. Benarroch E.E. Nitric oxide: a pleiotropic signal in the nervous system. Neurology 2011, 77:1568-1576.
2. Berridge M.J. Calcium regulation of neural rhythms, memory and Alzheimer's disease. J. Physiol. 2013, 3.
3. Cao J., Viholainen J.I., Dart C., Warwick H.K., Leyland M.L., Courtney M.J. The PSD95-nNOS interface: a target for inhibition of excitotoxic p38 stress-activated protein kinase activation and cell death. J. Cell Biol. 2005, 168:117-126.
4. Carter A.G., Regehr W.G. Prolonged synaptic currents and glutamate spillover at the parallel fiber to stellate cell synapse. J. Neurosci. 2000, 20:4423-4434.
5. Chintamaneni M., Bhaskar M. Biomarkers in Alzheimer's disease: a review. ISRN Pharmacol. 2012, 2012:984786.
6. Courtney M.J., Li L.L., Lai Y.Y. Mechanisms of NOS1AP action on NMDA receptor-nNOS signaling. Front. Cell. Neurosci. 2014, 8:252.
7. Eastwood S.L. Does the CAPON gene confer susceptibility to schizophrenia?. PLoS Med. 2005, 2:e348.
8. Fassbender K., Masters C., Beyreuther K. Alzheimer's disease: an inflammatory disease?. Neurobiol. Aging 2000, 21:433-436. discussion 451-3.
9. Garvey E.P., Oplinger J.A., Furfine E.S., Kiff R.J., Laszlo F., Whittle B.J., Knowles R.G. 1400W is a slow, tight binding, and highly selective inhibitor of inducible nitric-oxide synthase in vitro and in vivo. J. Biol. Chem. 1997, 272:4959-4963.
10. Gladding C.M., Raymond L.A. Mechanisms underlying NMDA receptor synaptic/extrasynaptic distribution and function. Mol. Cell. Neurosci. 2011, 48:308-320.
11. Hardy J., Selkoe D.J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002, 297:353-356.
12. Jing Y., Fleete M.S., Collie N.D., Zhang H., Liu P. Regional variations and age-related changes in arginine metabolism in the rat brain stem and spinal cord. Neuroscience 2013, 252:98-108.
13. Jourdain P., Bergersen L.H., Bhaukaurally K., Bezzi P., Santello M., Domercq M., Matute C., Tonello F., Gundersen V., Volterra A. Glutamate exocytosis from astrocytes controls synaptic strength. Nat. Neurosci. 2007, 10:331-339.
14. Kim S.H., Han J., Seog D.H., Chung J.Y., Kim N., Hong Park Y., Lee S.K. Antidepressant effect of Chaihu-Shugan-San extract and its constituents in rat models of depression. Life Sci. 2005, 76:1297-1306.
15. Lee Y.J., Choi D.Y., Choi I.S., Kim K.H., Kim Y.H., Kim H.M., Lee K., Cho W.G., Jung J.K., Han S.B., Han J.Y., Nam S.Y., Yun Y.W., Jeong J.H., Oh K.W., Hong J.T. Inhibitory effect of 4-O-methylhonokiol on lipopolysaccharide-induced neuroinflammation, amyloidogenesis and memory impairment via inhibition of nuclear factor-kappaB in vitro and in vivo models. J. Neuroinflamm. 2012, 9:35.
16. Li M., Chen L., Lee D.H., Yu L.C., Zhang Y. The role of intracellular amyloid beta in Alzheimer's disease. Prog. Neurobiol. 2007, 83:131-139.
17. Lisman J., Yasuda R., Raghavachari S. Mechanisms of CaMKII action in long-term potentiation. Nat. Rev. Neurosci. 2012, 13:169-182.
18. Liu M., Bing G. Lipopolysaccharide animal models for Parkinson's disease. Parkinsons Dis. 2011, 2011:327089.
19. Liu P., Jing Y., Zhang H. Age-related changes in arginine and its metabolites in memory-associated brain structures. Neuroscience 2009, 164:611-628.
20. Luterman J.D., Haroutunian V., Yemul S., Ho L., Purohit D., Aisen P.S., Mohs R., Pasinetti G.M. Cytokine gene expression as a function of the clinical progression of Alzheimer disease dementia. Arch. Neurol. 2000, 57:1153-1160.
21. Medeiros R., Baglietto-Vargas D., LaFerla F.M. The role of tau in Alzheimer's disease and related disorders. CNS Neurosci. Ther. 2011, 17:514-524.
22. Meunier C.J., Burton J., Cumps J., Verbeeck R.K. Evaluation of the formalin test to assess the analgesic activity of diflunisal in the rat. Eur J Pharm Sci 1998, 6:311-316.
23. Mukherjee P., Cinelli M.A., Kang S., Silverman R.B. Development of nitric oxide synthase inhibitors for neurodegeneration and neuropathic pain. Chem. Soc. Rev. 2014, 43:6814-6838.
24. Nadeau S., Rivest S. Effects of circulating tumor necrosis factor on the neuronal activity and expression of the genes encoding the tumor necrosis factor receptors (p55 and p75) in the rat brain: a view from the blood-brain barrier. Neuroscience 1999, 93:1449-1464.
25. Nemec A., Pavlica Z., Petelin M., Crossley D.A., Sentjurc M., Jerin A., Erzen D., Zdovc I., Hitti T., Skaleric U. Systemic use of selective iNOS inhibitor 1400W or non-selective NOS inhibitor l-NAME differently affects systemic nitric oxide formation after oral Porphyromonas gingivalis inoculation in mice. Arch Oral Biol 2010, 55:509-514.
26. Nuernberg B., Koehler G., Brune K. Pharmacokinetics of diflunisal in patients. Clin. Pharmacokinet. 1991, 20:81-89.
27. Ohta H., Arai S., Akita K., Ohta T., Fukuda S. Effects of NK-4 in a transgenic mouse model of Alzheimer's disease. PLoS One 2012, 7:e30007.
28. Paoletti P., Bellone C., Zhou Q. NMDA receptor subunit diversity: impact on receptor properties, synaptic plasticity and disease. Nat. Rev. Neurosci. 2013, 14:383-400.
29. Parameshwaran K., Dhanasekaran M., Suppiramaniam V. Amyloid beta peptides and glutamatergic synaptic dysregulation. Exp. Neurol. 2008, 210:7-13.
30. Petralia R.S., Wang Y.X., Hua F., Yi Z., Zhou A., Ge L., Stephenson F.A., Wenthold R.J. Organization of NMDA receptors at extrasynaptic locations. Neuroscience 2010, 167:68-87.
31. Pfeiffer S., Leopold E., Schmidt K., Brunner F., Mayer B. Inhibition of nitric oxide synthesis by NG-nitro-l-arginine methyl ester (l-NAME): requirement for bioactivation to the free acid, NG-nitro-l-arginine. Br. J. Pharmacol. 1996, 118:1433-1440.
32. Qin L., Wu X., Block M.L., Liu Y., Breese G.R., Hong J.S., Knapp D.J., Crews F.T. Systemic LPS causes chronic neuroinflammation and progressive neurodegeneration. Glia 2007, 55:453-462.
33. Rayatnia F., Javadi-Paydar M., Allami N., Zakeri M., Rastegar H., Norouzi A., Dehpour A.R. Nitric oxide involvement in consolidation, but not retrieval phase of cognitive performance enhanced by atorvastatin in mice. Eur. J. Pharmacol. 2011, 666:122-130.
34. Rushaidhi M., Jing Y., Kennard J.T., Collie N.D., Williams J.M., Zhang H., Liu P. Aging affects l-arginine and its metabolites in memory-associated brain structures at the tissue and synaptoneurosome levels. Neuroscience 2012, 209:21-31.
35. Schagger H. Tricine-SDS-PAGE. Nat. Protoc. 2006, 1:16-22.
36. Schagger H., von Jagow G. Tricine-sodium dodecyl sulfate-polyacrylamide gel electrophoresis for the separation of proteins in the range from 1 to 100kDa. Anal. Biochem. 1987, 166:368-379.
37. Sheng J.G., Bora S.H., Xu G., Borchelt D.R., Price D.L., Koliatsos V.E. Lipopolysaccharide-induced-neuroinflammation increases intracellular accumulation of amyloid precursor protein and amyloid beta peptide in APPswe transgenic mice. Neurobiol. Dis. 2003, 14:133-145.
38. Talantova M., Sanz-Blasco S., Zhang X., Xia P., Akhtar M.W., Okamoto S., Dziewczapolski G., Nakamura T., Cao G., Pratt A.E., Kang Y.J., Tu S., Molokanova E., McKercher S.R., Hires S.A., Sason H., Stouffer D.G., Buczynski M.W., Solomon J.P., Michael S., Powers E.T., Kelly J.W., Roberts A., Tong G., Fang-Newmeyer T., Parker J., Holland E.A., Zhang D., Nakanishi N., Chen H.S., Wolosker H., Wang Y., Parsons L.H., Ambasudhan R., Masliah E., Heinemann S.F., Pina-Crespo J.C., Lipton S.A. Abeta induces astrocytic glutamate release, extrasynaptic NMDA receptor activation, and synaptic loss. Proc. Natl. Acad. Sci. U. S. A. 2013, 110:E2518-E2527.
39. Tamura H., Ishikawa Y., Hino N., Maeda M., Yoshida S., Kaku S., Shiosaka S. Neuropsin is essential for early processes of memory acquisition and Schaffer collateral long-term potentiation in adult mouse hippocampus in vivo. J. Physiol. 2006, 570:541-551.
40. Traystman R.J., Moore L.E., Helfaer M.A., Davis S., Banasiak K., Williams M., Hurn P.D. Nitro-L-arginine analogues. Dose- and time-related nitric oxide synthase inhibition in brain. Stroke 1995, 26:864-869.
41. Van der Borght K., Havekes R., Bos T., Eggen B.J., Van der Zee E.A. Exercise improves memory acquisition and retrieval in the Y-maze task: relationship with hippocampal neurogenesis. Behav. Neurosci. 2007, 121:324-334.
42. Vizi E.S., Kisfali M., Lorincz T. Role of nonsynaptic GluN2B-containing NMDA receptors in excitotoxicity: evidence that fluoxetine selectively inhibits these receptors and may have neuroprotective effects. Brain Res. Bull. 2013, 93:32-38.
43. Yi J., Horky L.L., Friedlich A.L., Shi Y., Rogers J.T., Huang X. l-Arginine and Alzheimer's disease. Int. J. Clin. Exp. Pathol. 2009, 2:211-238.
44. Yildiz Akar F., Celikyurt I.K., Ulak G., Mutlu O. Effects of l-arginine on 7-nitroindazole-induced reference and working memory performance of rats. Pharmacology 2009, 84:211-218.
45. Zhang Y.W., Thompson R., Zhang H., Xu H. APP processing in Alzheimer's disease. Mol. Brain 2011, 4:3.
46. Zilka N., Kazmerova Z., Jadhav S., Neradil P., Madari A., Obetkova D., Bugos O., Novak M. Who fans the flames of Alzheimer's disease brains? Misfolded tau on the crossroad of neurodegenerative and inflammatory pathways. J. Neuroinflamm. 2012, 9:47.